Can Chinese Phase I data from the West accelerate China drug development?
The science of ethnobridging – a way to implement cost-effective, multi-ethnic approaches to global clinical trial research and drug development.
Related Insights
Blog
A hybrid model supports globally diverse site participation for a retrospective cancer study
Jul 24, 2023
Podcast
Enabling Successful Sites, Ep2: Empowering Sites to be More Inclusive Through Cultural Sensitivity Training
Jun 28, 2024
Article
Australia: A highly attractive environment for drug development
Aug 24, 2023
Video
How early-stage diversity strategies can save time and budget later
Oct 3, 2023
Video
The science and practice of ethnobridging
May 17, 2023
Blog
Recruiting underrepresented populations for phase I studies: How earlier diversity planning leads will benefit your programs later
Dec 9, 2024
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Blog
Xoli Belgrave appointed to lead Parexel’s Clinical Trial Diversity, Equity & Inclusion strategy
Jan 10, 2023
Blog
Inclusion for all: Expanding trial accessibility for transgender and nonbinary patients
Sep 23, 2022
Blog
Preparing for a new era in European Market Access
Jul 22, 2022
Blog
Toward more inclusive studies: Reaching and retaining patients from underrepresented communities
Apr 25, 2022
Blog
Six steps to maximize inclusivity within medical communications | Part 1: Race and Ethnicity
Mar 3, 2022
Related Insights
Blog
A hybrid model supports globally diverse site participation for a retrospective cancer study
Jul 24, 2023
Podcast
Enabling Successful Sites, Ep2: Empowering Sites to be More Inclusive Through Cultural Sensitivity Training
Jun 28, 2024
Article
Australia: A highly attractive environment for drug development
Aug 24, 2023
Video
How early-stage diversity strategies can save time and budget later
Oct 3, 2023
Video
The science and practice of ethnobridging
May 17, 2023
Blog
Recruiting underrepresented populations for phase I studies: How earlier diversity planning leads will benefit your programs later
Dec 9, 2024
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Blog
Xoli Belgrave appointed to lead Parexel’s Clinical Trial Diversity, Equity & Inclusion strategy
Jan 10, 2023
Blog
Inclusion for all: Expanding trial accessibility for transgender and nonbinary patients
Sep 23, 2022
Blog
Preparing for a new era in European Market Access
Jul 22, 2022
Blog
Toward more inclusive studies: Reaching and retaining patients from underrepresented communities
Apr 25, 2022
Blog
Six steps to maximize inclusivity within medical communications | Part 1: Race and Ethnicity
Mar 3, 2022